Eco Animal Health Group PLC (GB:EAH)
LSE:EAH
Top Page
Eco Animal Health
(LSE:EAH)
Select Model
Select Model
Rating:76Outperform
Price Target:
99.00 p
▲(26.11% Upside)
Action:ReiteratedDate:12/07/25
Eco Animal Health's overall stock score is driven by strong technical momentum and positive corporate events, indicating confidence in future growth. However, the high valuation and inconsistent financial performance temper the score, suggesting potential risks if growth expectations are not met.
Positive Factors
Balance Sheet Strength
A conservatively leveraged balance sheet with a healthy equity ratio gives Eco Animal Health durable financial flexibility. It supports multi-period regulatory approvals, funds commercial rollouts and R&D without immediate refinancing, and lowers insolvency risk during industry cycles.
Negative Factors
Inconsistent Revenue Growth
Irregular revenue trends and a recent decline weaken predictability of cash flows and complicate multi-year planning. This amplifies risk around steady funding for registrations, commercialization efforts and scaling the distribution network, making long-term execution harder.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A conservatively leveraged balance sheet with a healthy equity ratio gives Eco Animal Health durable financial flexibility. It supports multi-period regulatory approvals, funds commercial rollouts and R&D without immediate refinancing, and lowers insolvency risk during industry cycles.
Read all positive factors
Eco Animal Health (EAH) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£59.63M
Dividend YieldN/A
Average Volume (3M)75.04K
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue Growth1.44%
EPS Growth359.79%
CountryUK
Employees227
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding67,759,674
10 Day Avg. Volume57,390
30 Day Avg. Volume75,042
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)0.42
Price to Sales (P/S)0.45
P/FCF Ratio6.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)£89.82M
Eco Animal Health Business Overview & Revenue Model
Company Description
Eco Animal Health (EAH) is a global provider of innovative animal health products, specializing in sustainable solutions for livestock and aquaculture. The company focuses on developing environmentally friendly medications and nutritional products...
How the Company Makes Money
EAH primarily makes money by selling animal health pharmaceutical products for livestock markets. Revenue is generated through (1) product sales via EAH’s own sales and distribution operations in markets where it has direct presence, and (2) sales...
Eco Animal Health Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
75
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Sep 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 85.81M | 79.60M | 89.42M | 85.31M | 82.19M | 105.61M |
| Gross Profit | 42.10M | 35.91M | 37.68M | 36.75M | 33.70M | 51.54M |
| EBITDA | 9.60M | 7.29M | 6.53M | 7.41M | 3.62M | 18.63M |
| Net Income | 3.02M | 1.69M | 1.05M | 1.01M | -686.00K | 7.34M |
Balance Sheet | ||||||
| Total Assets | 113.96M | 120.60M | 123.27M | 121.31M | 113.60M | 116.89M |
| Cash, Cash Equivalents and Short-Term Investments | 18.64M | 25.01M | 22.37M | 21.66M | 14.31M | 19.52M |
| Total Debt | 5.06M | 3.79M | 4.03M | 4.48M | 1.91M | 1.52M |
| Total Liabilities | 21.57M | 25.84M | 29.89M | 25.76M | 19.25M | 21.57M |
| Stockholders Equity | 84.75M | 85.50M | 83.69M | 83.27M | 82.06M | 81.90M |
Cash Flow | ||||||
| Free Cash Flow | 8.66M | 5.44M | 4.94M | 10.03M | -3.25M | 11.04M |
| Operating Cash Flow | 8.99M | 10.45M | 9.42M | 16.01M | -358.00K | 12.11M |
| Investing Cash Flow | -5.20M | -4.61M | -3.42M | -5.98M | -2.88M | -1.06M |
| Financing Cash Flow | -3.33M | -1.95M | -3.69M | -2.40M | -3.31M | -684.00K |
Eco Animal Health Technical Analysis
Negative
78.50
Price Trends
102.59
Negative
102.24
Negative
89.98
Negative
Market Momentum
-2.42
Positive
27.53
Positive
12.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EAH, the sentiment is Negative. The current price of 78.5 is below the 20-day moving average (MA) of 97.33, below the 50-day MA of 102.59, and below the 200-day MA of 89.98, indicating a bearish trend. The MACD of -2.42 indicates Positive momentum. The RSI at 27.53 is Positive, neither overbought nor oversold. The STOCH value of 12.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:EAH.
Eco Animal Health Peers Comparison
UnderperformOutperform
Sector (51)
GB:EAH
Eco Animal Health
92.00
40.50
78.64%
GB:ANCR
Animalcare
246.00
38.29
18.43%
Eco Animal Health Corporate Events
Business Operations and StrategyExecutive/Board Changes
ECO Animal Health Announces Retirement of Non‑Executive Director Frank Armstrong
Positive
Mar 31, 2026
ECO Animal Health has announced that Independent Non‑Executive Director Frank Armstrong will retire from the board following the company’s Annual General Meeting, expected in September, as he prepares to assume the role of Senior Lay M...
Business Operations and StrategyFinancial Disclosures
Eco Animal Health lifts full-year outlook as margins beat forecasts
Positive
Mar 19, 2026
Eco Animal Health said trading for the year to 31 March 2026 remained strong, extending a robust first half, with full-year revenue expected to grow by about 8% year on year to slightly above market expectations. Growth was driven in particular by...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
ECO Animal Health Wins Key USDA Safety Milestone for New Poultry Vaccine
Positive
Mar 11, 2026
ECO Animal Health has received a favourable safety assessment from the U.S. Department of Agriculture for ECOVAXXIN MG, its live poultry vaccine targeting the respiratory pathogen Mycoplasma gallisepticum. This review confirms that the vaccine mee...
Business Operations and StrategyRegulatory Filings and Compliance
Eco Animal Health Leaves 375,505 Shares Available Under Option Schemes
Positive
Mar 5, 2026
Eco Animal Health Group has provided an update on its block listing related to its Executive and Unapproved Share Option Schemes, originally covering 1.5 million ordinary shares admitted in 2017. Over the latest reporting period to 12 February 202...
Business Operations and StrategyProduct-Related Announcements
ECO Animal Health sets EU launch plan for new poultry vaccine ECOVAXXIN MS
Positive
Feb 26, 2026
ECO Animal Health Group has outlined its EU commercial launch strategy for ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae in layer and breeder chickens, following European Commission marketing authorisation granted in late 202...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.